Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

Phase 2

Completed

• Conditions: Psoriasis
• Interventions: Drug: RA-18C3

• Registration Number: NCT01384630
• Lead Sponsor: Janssen Research & Development, LLC

Brief Summary

This is a 73-day phase II, open label trial of the true human monoclonal antibody RA-18C3 in subjects with moderate to severe plaque psoriasis. Ten (10) subjects will receive 200 mg of RA-18C3 via subcutaneous injection. Subjects will receive injections at Days 0, 21, and 42 for a total of 3 injections. Study drug will be administered under close observation in a facility equipped to handle medical emergencies. Subjects will not be discharged from the facility until at least 1 hour following the end of the injection or 1 hour after their vital signs have stabilized. Safety will be assessed by pre- and post-treatment serial measurements of vital signs, clinical laboratory assessments, and the recording of adverse clinical events.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-06-08
• Study First Submitted QC: 2011-06-28
• Study First Posted: 2011-06-29
• Study Start: 2011-09-30
• Primary Completion: 2012-07-31
• Study Completion: 2012-08-31
• Disposition First Submitted: 2014-06-05
• Disposition First Submitted QC: 2014-06-05
• Disposition First Posted: 2014-06-18
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-28
• Last Update Posted: 2025-03-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

1. Subjects 18 years of age or older
2. Diagnosis of plaque psoriasis for ≥ 6 months; INCLUDING subjects with chronic guttate lesions.
3. Psoriasis area-and-severity index (PASI) score of ≥ 12
4. Involvement of ≥ 5% of body-surface area
5. For female subjects of childbearing age, a negative urine pregnancy test at screening and at specified time points throughout the trial. For subjects with reproductive potential, a willingness to utilize adequate, double barrier contraception during the study and including 3 months after study completion. Sexually active men must use an accepted method of contraception during the study and including 3 months after study completion.
6. Signed and dated Institutional Review Board (IRB) approved informed consent before any protocol-specific screening procedures are performed

Exclusion Criteria

1. Treatment with any biologicals or investigational agents within the last 4 weeks (or 5 half-lives, whichever is longer).

2. Treatment with conventional systemic psoriasis therapy within last 4 weeks

3. Treatment with phototherapy within the last 4 weeks

4. Topical psoriasis treatment with the last 2 weeks

5. History of uncontrolled diabetes, unstable ischemic heart disease, active inflammatory bowel disease, active peptic ulcer disease, recent stroke (within 3 months), ongoing congestive heart failure, and any other condition which, in the opinion of the investigator, would put the subject at risk by participation in the protocol.

6. Hemoglobin <10.0 g/dL, WBC <3.0 x 103/mm3, platelet count <125 x 103/mm3, creatinine > 1.5mg/dL, AST/ALT >2 x ULN, alkaline phosphatase >2 x ULN

7. Known HIV antibody, hepatitis B surface antigen and/or hepatitis C antibody.

8. History of malignancy within 5 years prior to study entry other than carcinoma in situ of the cervix, or adequately treated, non-metastatic squamous or basal cell carcinoma of the skin.

9. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies.

10. History of tuberculosis (latent or active) or positive Interferon-gamma release assay (IGRA)

11. Infectious disease:

    CRP >30 mg/L, fever, or infection requiring treatment with antibiotics within 3 weeks prior to Screening

12. Immunodeficiency

13. History of treatment with Tysabri or Raptiva

14. Female subjects who are pregnant, planning to become pregnant during the course of the study, or breast-feeding

15. Receipt of a live (attenuated) vaccine within 3 months prior to Screening

16. Major surgery within 28 days prior to Day 0

17. Participation in an investigational drug or device trial within 30 days prior to Screening

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Single group	RA-18C3	-

Primary Outcome Measures

Name	Time	Method
Safety and Tolerability	56 days	Incidence and type of adverse clinical events

Secondary Outcome Measures

Name	Time	Method
Psoriasis Area and Severity Index (PASI)	56 days	Percentage of subjects that acheive PASI 50, PASI 75, and PASI 90
Erythrocyte Sedimentation Rate	56 days
Dermatology Life Quality Index Questionnaire (DLQI)	56 days	Change in DLQI from baseline to day 56
C-reactive protein	56 days
RA-18C3 Pharmacokinetics	56 days	Serum levels of RA-18C3 will be measured to determine drug half-life, bioavailability, volume of distribution, and area under the curve.
Physician's Global Assessment Score (PGA)	56 days	Change in PGA from baseline to day 56

Trial Locations

Locations (3)

West Kentucky Dermatology; 🇺🇸 Owensboro, Kentucky, United States

Westlake Dermatology; 🇺🇸 Austin, Texas, United States

University of Michigan; 🇺🇸 Ann Arbor, Michigan, United States